

## Prior Authorization Request

FASLODEX (fulvestrant) and generics

### Instructions

**Please complete Part A and have your physician complete Part B.** This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

### Part A – Patient

#### **Patient Information**

First Name:		Last Name:	
Insurance Carrier Name/Number:			
Group Number:		Client ID:	
Date of Birth (YYYY/MM/DD):		Relationship: <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent	
Language: <input type="checkbox"/> English <input type="checkbox"/> French		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:			
City:	Province:	Postal Code:	
Email address:			
Telephone (home):	Telephone (cell):	Telephone (work):	

Please check any box that applies to the patient:

- The patient is an over-age student dependent (i.e. attending University or College full-time). A copy of the enrolment document from the educational institution confirming full-time status is enclosed.
- The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.

#### **Coordination of benefits**

<b>Provincial Coverage</b>	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.
<b>Primary Coverage</b>	Has the patient applied for reimbursement under a primary plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>

## Prior Authorization Request

FASLODEX (fulvestrant) and generics

### Authorization

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

---

Plan Member Signature

---

Date

---

Patient Signature (if over 18 years of age)

---

Date

## Prior Authorization Request

FASLODEX (fulvestrant) and generics

### Part B – Prescriber

Please see instructions on page 1 and complete all sections below. Incomplete forms may result in automatic denial. Please do **not** provide genetic test information or results.

### SECTION 1 – DRUG REQUESTED

<b>FASLODEX (fulvestrant) and generics</b> <input type="checkbox"/> New request <input type="checkbox"/> Renewal request*				
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
Site of drug administration: <input type="checkbox"/> Home <input type="checkbox"/> Physician’s office/Private Clinic <input type="checkbox"/> Private Clinic (within Hospital - no public or government funding) <input type="checkbox"/> Hospital (inpatient) <input type="checkbox"/> Hospital (outpatient)				
Name of the hospital or private clinic:				
Address:				
City:	Province:	Postal code:		

\* Please submit proof of prior coverage if available

### SECTION 2 – ELIGIBILITY CRITERIA

**1. Please indicate if the patient satisfies the below criteria:**

**Breast Cancer – Metastatic, First-Line**

For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine therapy, AND

The patient is a postmenopausal woman

**Breast Cancer – Metastatic, Second-Line**

For the treatment of patients with locally advanced or metastatic breast cancer, AND

The patient is a postmenopausal woman, AND

The patient has had disease progression following prior anti-estrogen therapy

**Breast Cancer – Metastatic, PIK3CA-Mutated, Second-Line**

For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer, AND

The patient is a man or a postmenopausal woman, AND

The patient’s disease previously progressed on or after prior endocrine therapy, AND

Fulvestrant will be used in combination with PIQRAY (alpelisib)

## Prior Authorization Request

FASLODEX (fulvestrant) and generics

**Breast Cancer – Metastatic, Second-Line**

- For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in an adult, AND
- The patient is a man or a postmenopausal woman, OR
- The patient is a pre- or peri-menopausal woman and receiving treatment with a luteinizing hormone releasing hormone (LHRH) agonist, AND
- The patient's disease previously progressed on or after prior endocrine therapy, AND
- Fulvestrant will be used in combination with IBRANCE (palbociclib)

**Breast Cancer – Metastatic, Second-Line**

- For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in an adult, AND
- The patient is a postmenopausal woman, OR
- The patient is a pre- or peri-menopausal woman and receiving treatment with a luteinizing hormone releasing hormone (LHRH) agonist, AND
- The patient's disease previously progressed on or after prior endocrine therapy, AND
- Fulvestrant will be used in combination with VERZENIO (abemaciclib)

**OR**

- None of the above criteria applies.

Relevant additional information:

**SECTION 3 – PRESCRIBER INFORMATION**

Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

## Prior Authorization Request

FASLODEX (fulvestrant) and generics

### SECTION 4 – RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at [www.sunlife.ca/privacy](http://www.sunlife.ca/privacy) or call us for a copy.

**Questions?** Please visit [www.sunlife.ca](http://www.sunlife.ca) or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET

### SECTION 5 – CONTACT US



You can submit **all** pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the reference number.

**OR**

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

**FAX: 1-855-342-9915**

**Mail:**  
Sun Life Assurance Company of  
Canada  
Attention: Claims Dept.  
PO Box 11658 STN CV  
Montreal, QC H3C 6C1

Sun Life Assurance Company of  
Canada  
Attention: Claims Dept.  
PO Box 2010 STN Waterloo  
Waterloo, ON N2J 0A6